Zanubrutinib is a targeted therapeutic agent (a Bruton’s tyrosine kinase [BTK] inhibitor) primarily indicated for the treatment of certain B-cell lymphomas. Its common side effects include an elevated infection risk, hematologic abnormalities, and gastrointestinal discomfort, among others. Specific manifestations vary between individuals. The drug must be administered under medical supervision with timely safety monitoring.
Common Side Effects and Management
Elevated Infection Risk
Infections may occur in sites such as the respiratory tract and urinary tract, presenting with symptoms including fever, cough, and dysuria.
Regular complete blood count (CBC) monitoring is required. If infection symptoms develop, prompt medical attention and antibiotic therapy are necessary.
Hematologic Abnormalities
Neutropenia (which increases infection risk), thrombocytopenia (predisposing to bruising or bleeding), and anemia (manifesting as fatigue and dizziness) are frequently observed.
In severe cases, dose modification or temporary treatment interruption may be required; blood component transfusion may be administered when clinically indicated.
Gastrointestinal Reactions
Diarrhea, nausea, vomiting, abdominal pain, and other symptoms are usually mild in severity and can be relieved via dietary adjustments or supportive medications.
If symptoms persist or worsen, contact a physician to evaluate the need for clinical intervention.
Cardiovascular Events
A small proportion of patients may develop arrhythmias (e.g., atrial fibrillation), hypertension, or heart failure.
Cardiac function should be monitored regularly during treatment, particularly in patients with a preexisting cardiovascular history.
Other Adverse Reactions
Musculoskeletal pain, rash, fatigue, and other symptoms are common and mostly resolve spontaneously.
In rare instances, patients may experience elevated liver enzymes or interstitial lung disease, which mandates immediate drug discontinuation and urgent medical care.
Precautions
Strict Adherence to Prescribing Instructions
Zanubrutinib is a prescription medication. Dosage should be adjusted based on disease status and treatment tolerability; do not discontinue therapy or modify the dosing regimen without medical authorization.
Clinical Monitoring and Emergency Guidance
Undergo regular follow-up tests including CBC, liver and renal function, and electrocardiography during treatment. Seek emergency medical care immediately if symptoms such as chest pain, dyspnea, severe bleeding, or sustained high fever develop.
Overall, the side effects of zanubrutinib are manageable, but close clinical monitoring and consistent communication with the treating physician are critical to balance therapeutic efficacy and treatment safety.
